- £216.87bn
- £236.39bn
- $58.74bn
China biotech's ingenuity extends to dealmaking
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Brief: EMA's CHMP Recommends Extension Of Therapeutic Indication For Pandemic Influenza Vaccine H5N1 AstraZeneca
China biotech's ingenuity extends to dealmaking
Brief: AstraZeneca Secures Exclusive Global Rights to Selected Programs Under Insitro Collaboration
Brief: Insitro Announces a Strategic Collaboration with AstraZeneca for AI-enabled Discovery of Novel Therapeutics for MASH and Cardiomyopathies
AstraZeneca strikes $40 million AI drug discovery deal with insitro
Factbox: Pharma sector doubles down on AI to slash costs, timelines
Brief: Astrazeneca Says Efzimfotase Alfa Shows Improvement In Primary And Key Secondary Endpoints At Week 25 And Week 49
Brief: Guardant Health Announces Approval In Europe Of Guardant360® Cdx
Focus: AI companies run virtual drug trials, aim to improve success of human studies
Brief: Multiply Labs Raises $75 Mln Series B Led By AstraZeneca, Teradyne
London stocks gain on softer oil, easing gilt yields; Defence shares fall
Factbox: Global healthcare companies invest billions to boost US presence
UK shares rise as softer oil, easing gilt yields lift sentiment
Europe Research Roundup: AstraZeneca, Hensoldt, Sika
AstraZeneca to invest over $1 billion in Massachusetts, boost workforce (updated)
Brief: Astrazeneca Opens Global Strategic R&D Center In Kendall Square, Massachusetts
AstraZeneca opens new Massachusetts R&D center as part of $1 billion investment